Reply to thread

Message: [QUOTE="greenmedinfo, post: 3751"] PMID: Int J Environ Health Res. 2021 Oct 24:1-19. Epub 2021 Oct 24. PMID: 34689674 Abstract Title: treatment with fucoidan of mononuclear cells from SARS-CoV-2 infected patients. Abstract: COVID-19 is a worldwide health emergency, therapy for this disease is based on antiviral drugs and immunomodulators, however, there is no treatment to effectively reduce the COVID-19 mortality rate. Fucoidan is a polysaccharide obtained from marine brown algae, with anti-inflammatory, antiviral, and immune-enhancing properties, thus, fucoidan may be used as an alternative treatment (complementary to prescribed medical therapy) for the recovery of COVID-19. This work aimed to determine the effects of ex-vivo treatment with fucoidan on cytotoxicity, apoptosis, necrosis, and senescence, besides functional parameters of calcium flux and mitochondrial membrane potential (ΔΨm) on human peripheral blood mononuclear cells isolated from SARS-CoV-2 infected, recovered and healthy subjects. Data suggest that fucoidan does not exert cytotoxicity or senescence, however, it induces the increment of intracellular calcium flux. Additionally, fucoidan promotes recovery of ΔΨm in PBMCs from COVID-19 recovered females. Data suggest that fucoidan could ameliorate the immune response in COVID-19 patients. [URL='https://www.greenmedinfo.com/article/ex-vivo-treatment-fucoidan-mononuclear-cells-sars-cov-2-infected-patients']read more[/URL] [/QUOTE]